Literature DB >> 26379115

The Frequency and Prognostic Impact of Pathological Microscopic Vascular Invasion According to Tumor Size in Non-Small Cell Lung Cancer.

Yoshihisa Shimada1, Hisashi Saji2, Yasufumi Kato3, Yujin Kudo3, Junichi Maeda3, Koichi Yoshida3, Masaru Hagiwara3, Jun Matsubayashi4, Masatoshi Kakihana3, Naohiro Kajiwara3, Tatsuo Ohira3, Norihiko Ikeda3.   

Abstract

BACKGROUND: Microscopic vascular invasion (MVI) in patients with non-small cell lung cancer (NSCLC) has been reported to be a strong predictor of poor outcomes but it has not been a descriptor of the TNM classification. The purposes of this study were to determine whether the presence of MVI is related to a predictor of poor outcomes and to explore the degree of MVI according to tumor size.
METHODS: A total of 1,884 patients with stage pT1-4N0-2 NSCLC who underwent complete resection comprised the study sample. Overall survival (OS) and recurrence-free proportion were estimated using the Kaplan-Meier method. The Cox proportional hazards model was used to assess independent predictors of poor outcomes.
RESULTS: Of 1,884 patients, 1,097 (58.2%) had MVI. Multivariate analysis showed MVI was a significant independent predictor of unfavorable OS (hazard ratio, 1.666; P < .001) and recurrence (hazard ratio, 2.268; P < .001). The frequency of MVI varied according to tumor size, and in each cohort of tumor sizes ≤ 2 cm, > 2 to 3 cm, and > 3 to 5 cm, there were significant differences in survival outcome by MVI status. The proportions of patients with a 5-year recurrence-free period with tumor sizes ≤ 2 cm, > 2 to 3 cm, and > 3 to 5 cm between MVI (+) and MVI (-) were 93.0% and 72.5% (P < .001), 90.8% and 63.3% (P < .001), and 86.4% and 59.9% (P < .001), respectively.
CONCLUSIONS: This study demonstrated that MVI was a strong predictor of poor outcomes and that the effect is more prominent in patients with tumor sizes ≤ 5 cm. Further analysis of survival and MVI should be collected for future revision of the TNM system.
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  microscopic vascular invasion; non-small cell lung cancer; overall survival; pathology lung cancer; recurrence-free proportion; tumor size

Mesh:

Year:  2016        PMID: 26379115     DOI: 10.1378/chest.15-0559

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Platelet Count is Associated with the Rate of Lymph Node Metastasis in Lung Adenocarcinoma.

Authors:  Cheng-Hao Qu; Tong Li; Zhan-Peng Tang; Xi-Rui Zhu; Jing-Yi Han; Hui Tian
Journal:  Cancer Manag Res       Date:  2020-10-07       Impact factor: 3.989

2.  The impact of positron emission tomography on primary tumour delineation and dosimetric outcome in intensity modulated radiotherapy of early T-stage nasopharyngeal carcinoma.

Authors:  Vincent W C Wu; Wan-Shun Leung; Kwun-Lam Wong; Ying-Kit Chan; Wing-Lam Law; Wing-Kwan Leung; Yat-Long Yu
Journal:  Radiat Oncol       Date:  2016-08-24       Impact factor: 3.481

3.  Prognostic factors for surgically resected non-small cell lung cancer with cavity formation.

Authors:  Shunsuke Shigefuku; Yujin Kudo; Daisuke Yunaiyama; Jun Matsubayashi; Jinho Park; Toshitaka Nagao; Yoshihisa Shimada; Hisashi Saji; Masaru Hagiwara; Tetsuya Okano; Masatoshi Kakihana; Naohiro Kajiwara; Tatsuo Ohira; Norihiko Ikeda
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

4.  Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma?

Authors:  Yusuke Tsuda; Kim Tsoi; Jonathan D Stevenson; Michael C Parry; Tomohiro Fujiwara; Vaiyapuri Sumathi; Lee M Jeys
Journal:  Clin Orthop Relat Res       Date:  2020-06       Impact factor: 4.755

5.  An improved method to build lung cancer PDX models by surgical resection samples and its association with B7-H3 expression.

Authors:  Yuxuan Wang; Biao Zhang; Haitao Huang; Tingjing Wang
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.